Pooled outcomes* and measures of association between remission categories and good radiographic and good functional outcomes, during the second year of follow-up
| Good radiographic outcome (GRO) defined as ∆mTSS ≤0.5 | |||
|
4V-remission
(n=1378) |
4V-near-remission
(n=1085) |
Non-remission
(n=3329) | |
| Percentage GRO (95% CI) | 81.1 (74.4 to 86.9) | 78.2 (69.5 to 85.8) | 71.8 (62.1 to 80.5) |
|
4V-near-remission vs
4V-remission |
4V-near-remission vs
Non-remission | ||
| ∆ percentage GRO (95% CI) | −2.9 (−7.3 to 1.5) | 6.2 (2.3 to 10.1) | |
| Relative risk GRO (95% CI) | 0.98 (0.94 to 1.02) | 1.07 (1.02 to 1.12) | |
| Good radiographic outcome (GRO) defined as ∆mTSS ≤0 | |||
| 4V-remission | 4V-near-remission | Non-remission | |
| Percentage GRO (95% CI) | 71.5 (63.5 to 78.8) | 64.1 (54.6 to 73.2) | 62.2 (51.5 to 72.4) |
|
4V-near-remission vs
4V-remission |
4V-near-remission vs
non-remission | ||
| ∆ percentage GRO (95% CI) | −7.7 (−16.6 to 1.1) | 1.7 (−8.1 to 11.5) | |
| Relative risk GRO (95% CI) | 0.91 (0.82 to 1.02) | 1.04 (0.94 to 1.16) | |
| Good radiographic outcome (GRO) defined as ∆mTSS ≤5 | |||
| 4V-remission | 4V-near-remission | Non-remission | |
| Percentage GRO (95% CI) | 97.5 (95.4 to 98.9) | 96.1 (92.5 to 98.5) | 94.2 (90.2 to 97.2) |
|
4V-near-remission vs
4V-remission |
4V-near-remission vs
Non-remission | ||
| ∆ percentage GRO (95% CI) | −2.5 (−7.5 to 2.6) | 4.1 (0.7 to 7.6) | |
| Relative risk GRO (95% CI) | 99.9 (0.97 to 1.01) | 1.01 (1.00 to 1.02) | |
| Good functional outcome (GFO) defined as ΔHAQ-DI ≤0 | |||
|
4V-remission
(n=1041) |
4V-near-remission
(n=758) |
Non-remission
(n=2105) | |
| Percentage GFO (95% CI) | 77.6 (74.3 to 80.8) | 66.9 (62.6 to 71.2) | 68.8 (66.0 to 71.7) |
|
4V-near-remission vs
4V-remission |
4V-near-remission vs
Non-remission | ||
| ∆ percentage GFO (95% CI) | −11.0 (−16.3 to −5.7) | −2.2 (−6.8 to 2.4) | |
| Relative risk GFO (95% CI) | 0.87 (0.81 to 0.94) | 0.98 (0.92 to 1.04) | |
| Good functional outcome (GFO) defined as ΔHAQ-DI ≤0 and HAQ-DI ≤0.5 | |||
|
4V-remission
(n=1305) |
4V-near-remission
(n=1003) |
Non-remission
(n=2954) | |
| Percentage GFO (95% CI) | 60.2 (53.3 to 67.0) | 22.5 (15.9 to 29.1) | 21.2 (16.1 to 26.3) |
|
4V-near-remission vs
4V-remission |
4V-near-remission vs
Non-remission | ||
| ∆ percentage GFO (95% CI) | −39.6 (−48.4 to −30.9) | 1.7 (−7.4 to 10.8) | |
| Relative risk GFO (95% CI) | 0.37 (0.30 to 0.46) | 1.12 (0.82 to 1.53) | |
4V-remission=SJC28, TJC28, CRP (mg/dL) and PGA (0–10), all ≤1; 4V-near-remission=SJC28, TJC28, CRP (mg/dL) ≤1 and PGA (0–10) >1; non-remission=SJC28 >1 or TJC28 >1 or CRP (mg/dL) >1, irrespective of PGA value; at 6 or 12 months of follow-up in all cases.
*Determined by meta-analyses: for each trial, we calculated the differences in the proportion/change (∆ proportion) of GRO or GFO between 4V-near-remission and 4V-remission states and between 4V-near-remission and non-remission states; then, we pooled these differences with a random-effects model to obtain an overall estimate of the difference (with 95% CI).
CRP, C reactive protein; ΔHAQ-DI, change in Health Assessment Questionnaire–Disability Index; PGA, patient global assessment; SJC28, swollen 28-joint count; TJC28, tender 28-joint count.